

DURECT CORP  
Form 8-K  
February 10, 2005

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## Form 8-K

---

### Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 10, 2005

Date of Report

(Date of earliest event reported)

---

## DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction of  
incorporation or organization)

000-31615  
(Commission File Number)

94-3297098  
(I.R.S. Employer  
Identification No.)

10240 Bubb Road  
Cupertino, CA 95014

Edgar Filing: DURECT CORP - Form 8-K

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On February 10, 2005, DURECT Corporation, a Delaware corporation (DURECT), announced the completion of dosing of the Phase I pharmacokinetic study for its sufentanil patch product and of the first cohort of the Phase II study for its post-operative pain relief depot. This Current Report is filed to disclose nonpublic information required to be disclosed by Regulation FD.

A copy of DURECT's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release of DURECT Corporation dated February 10, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DURECT Corporation**

Date: February 10, 2005

By: /s/ James E. Brown

---

James E. Brown  
President and Chief Executive Officer

**DURECT CORPORATION**

**INDEX TO EXHIBITS**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press Release of DURECT Corporation dated February 10, 2005